HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN […]

Related Keywords

Piper Sandler , Pharmaceuticals Price Performance , Pharmaceuticals Daily , Free Report , Get Free Report , Aslan Pharmaceuticals , Nasdaq Asln , Asln , Medical , Reiterated Rating , Hc Wainwright ,